source
- Arsenal Biosciences cuts 99 jobs as it pivots to in vivo CAR-T therapyArsenal Biosciences announced another round of layoffs, eliminating 99 positions, which represents the majority of its workforce after a prior 50% reduction last year. The cuts are part of a strat…
- Biomarin nabs big royalties in achondroplasia patent settlement with AscendisBiomarin has granted Ascendis a non-exclusive, worldwide license to use navepegritide, the active ingredient in the latter company’s recently approved achondroplasia drug Yuviwel, in exchange for 1…